Stronger-than-Expected Demand for HiSeq Contributes to 50 Percent Boost in Sequencing Sales for Illumina in Q2
August 03, 2010
Stronger-than-Expected Demand for HiSeq Contributes to 50 Percent Boost in Sequencing Sales for Illumina in Q2
So far, Illumina has shipped more than 100 HiSeq instruments for revenue, representing "the fastest instrument scale-up in the company's history for the most complex product it has ever built."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Sequencing Revenue Grows 70 Percent in Q4, Driven by HiSeq
February 15, 2011 / In Sequence - Illumina Starts Shipping 600 Gb HiSeq Reagent Kits; Takes First Orders for MiSeq
May 3, 2011 / In Sequence - Illumina Books Orders for More than 135 MiSeqs, Starts Early-Access Shipments
August 2, 2011 / In Sequence - In Sequence Annual Survey: Illumina Leads Market but Most Users Believe PacBio Will Provide Next Big Leap
January 25, 2011 / In Sequence - New Sequencing Platforms Drive Choice, Competition, Lawsuits in 2010
January 4, 2011 / In Sequence